FDA approves Roche genetic test as an alternative to pap smear for cervical cancer screening
WASHINGTON - Federal health regulators have cleared a genetic test from Roche as the first U.S.-approved alternative to the pap smear, the decades-old mainstay of cervical cancer screening.
The Food and Drug Administration approved Roche's cobas HPV test to detect the human papillomavirus, or HPV, in women 25 and older. HPV causes nearly all cases of cervical cancer. Such DNA-based tests have been used for several years to confirm results from the pap tests. But Thursday's decision means Roche can now market the test as a stand-alone option for cervical cancer screening, without the pap test.
The decision comes despite pushback from a number of women's health groups, who warned regulators that approving the DNA test as an alternative to pap testing could lead to confusion, higher costs and overtreatment.
Read more Business News
- Dream wedding for dying manVernon / N. Okanagan - 7:23 am
- Puppy attacked at parkKelowna - 11:34 am
- Terrorist acts in the 1950sPenticton / S. Okanagan - 5:00 am
- Stanley returns to KelownaSports - 5:00 am
|QHR Technologies Inc||1.20||-0.01|
|Anavex Life Sciences||0.265||+0.005|
|Copper Mountain Mining||3.02||+0.14|
|Sunrise Resources Ltd||0.025||-0.005|
|Mission Ready Services||0.24||+0.025|
Photo: ContributedI would call it a joy ride... You see a planned project or business has a destination. It may be an ongoing revenue stream, it may be a business value or an exit strategy. If you don...
Establishing a joint account may seem like a great strategy at first glance. However, there are many factors that must be considered before taking this action. This article will explore the use of &ls...
Let’s face it; nobody wants to pay for legal services if they do not have to, but if you have been injured in an accident you may have thought about hiring a lawyer to help you navigate your cla...